Natco Pharma shares surge over 10% on getting nod for diabetes drug Semaglutide in India

Shares of Natco Pharma, the Hyderabad-based drug maker, surged as much as 10.95% to hit an intraday high of ₹914 on the National Stock Exchange (NSE) on Monday, February 9. On the BSE, Natco Pharma shares climbed as much as 11.2% to hit an intraday high of ₹914.25 amid spike in trading activity.

Natco Pharma came in very high demand after the company on Saturday announced that it has received approval from Central Drugs Standard Control Organisation (CDSCO) for Semaglutide in India.

"Natco Pharma("NATCO") received approval for Semaglutide from CDSCO to manufacture and market generic Semaglutide Injection in India. NATCO will launch the product in the India market in March’26," the Hyderabad-based drug maker said in a regulatory filing.

Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.

Natco Pharma shares were witnessing higher than usual trading activity as trading volume in the stock jumped by 6.4 times to 43.91 lakh shares compared with an average trading volume of 6.83 lakh shares.

On the BSE, as many as 3.29 lakh Natco Pharma shares changed hands compared with an average of 41,000 shares traded daily in the past two weeks.

Natco Pharma last week said that its consolidated net profit increased by14% year on year to ₹151 crore for the third quarter ended December 31, 2025.

The drug firm reported a net profit of ₹132 crore for the October-December quarter of the last fiscal.

Revenue from operations rose to ₹647 crore for the period under review as compared with ₹475 crore in the year-ago period, Natco Pharma said in a regulatory filing.

As of 10:06 am, Natco Pharma shares traded 10.76% higher at ₹912, outperforming the NIFTY Smallcap 100 index which was down 0.1%.